# Vertex Pharmaceuticals quarterly revenue

entity: /record/vertex-pharmaceuticals.md  
predicate: quarterly_revenue  
page: /record/vertex-pharmaceuticals/quarterly_revenue  
as_of: 2026-11-10  
cite: AsOf. "Vertex Pharmaceuticals quarterly revenue: 3,440,800,000 United States dollar", as of 2026-09-30. Claim clm_30E62BBC7C14, https://asof.is/claim/clm_30E62BBC7C14, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.  

As of November 10, 2026, Vertex Pharmaceuticals's quarterly revenue on the AsOf record is $3.44 billion, dated September 30, 2026, from a primary source (sec.gov).

54 claims on Vertex Pharmaceuticals's quarterly revenue, 1 open and 53 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted.

## Current quarterly revenue

What the record asserts on 2026-11-10.

- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 3,440,800,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_30E62BBC7C14](/claim/clm_30E62BBC7C14.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm

## Every dated value

One claim per line, oldest first. Superseded claims stay visible.

- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 23,979,000 United States dollar | valid 2009-03-31 to 2009-06-30 | conf 0.95 | superseded | superseded_by [clm_8CAD8C9EBAFE](/claim/clm_8CAD8C9EBAFE.md) | [clm_8EDF57286E75](/claim/clm_8EDF57286E75.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 19,064,000 United States dollar | valid 2009-06-30 to 2009-09-30 | conf 0.95 | superseded | superseded_by [clm_FCBA634A768D](/claim/clm_FCBA634A768D.md) | [clm_8CAD8C9EBAFE](/claim/clm_8CAD8C9EBAFE.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 24,957,000 United States dollar | valid 2009-09-30 to 2010-03-31 | conf 0.95 | superseded | superseded_by [clm_803A751AACB0](/claim/clm_803A751AACB0.md) | [clm_FCBA634A768D](/claim/clm_FCBA634A768D.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 22,429,000 United States dollar | valid 2010-03-31 to 2010-06-30 | conf 0.95 | superseded | superseded_by [clm_91E848597DF5](/claim/clm_91E848597DF5.md) | [clm_803A751AACB0](/claim/clm_803A751AACB0.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000104746910004633/0001047469-10-004633-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 31,622,000 United States dollar | valid 2010-06-30 to 2010-09-30 | conf 0.95 | superseded | superseded_by [clm_A2ABBC5D4946](/claim/clm_A2ABBC5D4946.md) | [clm_91E848597DF5](/claim/clm_91E848597DF5.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000104746910006916/0001047469-10-006916-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 23,795,000 United States dollar | valid 2010-09-30 to 2011-03-31 | conf 0.95 | superseded | superseded_by [clm_06E54341B7F1](/claim/clm_06E54341B7F1.md) | [clm_A2ABBC5D4946](/claim/clm_A2ABBC5D4946.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000104746910008963/0001047469-10-008963-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 73,662,000 United States dollar | valid 2011-03-31 to 2011-06-30 | conf 0.95 | superseded | superseded_by [clm_0CB375426AF0](/claim/clm_0CB375426AF0.md) | [clm_06E54341B7F1](/claim/clm_06E54341B7F1.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000104746911004721/0001047469-11-004721-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 114,424,000 United States dollar | valid 2011-06-30 to 2011-09-30 | conf 0.95 | superseded | superseded_by [clm_AFFDEC5591E2](/claim/clm_AFFDEC5591E2.md) | [clm_0CB375426AF0](/claim/clm_0CB375426AF0.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000104746911007153/0001047469-11-007153-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 659,200,000 United States dollar | valid 2011-09-30 to 2012-03-31 | conf 0.95 | superseded | superseded_by [clm_D0A8C98B8F52](/claim/clm_D0A8C98B8F52.md) | [clm_AFFDEC5591E2](/claim/clm_AFFDEC5591E2.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000104746911009007/0001047469-11-009007-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 438,737,000 United States dollar | valid 2012-03-31 to 2012-06-30 | conf 0.95 | superseded | superseded_by [clm_EDB18FEAB098](/claim/clm_EDB18FEAB098.md) | [clm_D0A8C98B8F52](/claim/clm_D0A8C98B8F52.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000104746912005755/0001047469-12-005755-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 418,305,000 United States dollar | valid 2012-06-30 to 2012-09-30 | conf 0.95 | superseded | superseded_by [clm_8B3F25617388](/claim/clm_8B3F25617388.md) | [clm_EDB18FEAB098](/claim/clm_EDB18FEAB098.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000104746912007979/0001047469-12-007979-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 336,006,000 United States dollar | valid 2012-09-30 to 2013-03-31 | conf 0.95 | superseded | superseded_by [clm_7FF4DCB7FD4C](/claim/clm_7FF4DCB7FD4C.md) | [clm_8B3F25617388](/claim/clm_8B3F25617388.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000104746912010125/0001047469-12-010125-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 328,368,000 United States dollar | valid 2013-03-31 to 2013-06-30 | conf 0.95 | superseded | superseded_by [clm_FF8C09587BDA](/claim/clm_FF8C09587BDA.md) | [clm_7FF4DCB7FD4C](/claim/clm_7FF4DCB7FD4C.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532013000024/0000875320-13-000024-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 310,750,000 United States dollar | valid 2013-06-30 to 2013-09-30 | conf 0.95 | superseded | superseded_by [clm_48045D19FF6B](/claim/clm_48045D19FF6B.md) | [clm_FF8C09587BDA](/claim/clm_FF8C09587BDA.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532013000038/0000875320-13-000038-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 221,700,000 United States dollar | valid 2013-09-30 to 2014-03-31 | conf 0.95 | superseded | superseded_by [clm_70C273FE1AD2](/claim/clm_70C273FE1AD2.md) | [clm_48045D19FF6B](/claim/clm_48045D19FF6B.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532013000045/0000875320-13-000045-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 118,451,000 United States dollar | valid 2014-03-31 to 2014-06-30 | conf 0.95 | superseded | superseded_by [clm_52B14B1D462C](/claim/clm_52B14B1D462C.md) | [clm_70C273FE1AD2](/claim/clm_70C273FE1AD2.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532014000026/0000875320-14-000026-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 138,421,000 United States dollar | valid 2014-06-30 to 2014-09-30 | conf 0.95 | superseded | superseded_by [clm_E49939D6DEDB](/claim/clm_E49939D6DEDB.md) | [clm_52B14B1D462C](/claim/clm_52B14B1D462C.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532014000058/0000875320-14-000058-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 178,987,000 United States dollar | valid 2014-09-30 to 2015-03-31 | conf 0.95 | superseded | superseded_by [clm_72E202E696DB](/claim/clm_72E202E696DB.md) | [clm_E49939D6DEDB](/claim/clm_E49939D6DEDB.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532014000063/0000875320-14-000063-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 138,509,000 United States dollar | valid 2015-03-31 to 2015-06-30 | conf 0.95 | superseded | superseded_by [clm_26173C591341](/claim/clm_26173C591341.md) | [clm_72E202E696DB](/claim/clm_72E202E696DB.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532015000029/0000875320-15-000029-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 166,076,000 United States dollar | valid 2015-06-30 to 2015-09-30 | conf 0.95 | superseded | superseded_by [clm_86562BC405C6](/claim/clm_86562BC405C6.md) | [clm_26173C591341](/claim/clm_26173C591341.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532015000047/0000875320-15-000047-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 309,816,000 United States dollar | valid 2015-09-30 to 2016-03-31 | conf 0.95 | superseded | superseded_by [clm_D1405FE577D0](/claim/clm_D1405FE577D0.md) | [clm_86562BC405C6](/claim/clm_86562BC405C6.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532015000056/0000875320-15-000056-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 398,080,000 United States dollar | valid 2016-03-31 to 2016-06-30 | conf 0.95 | superseded | superseded_by [clm_3D46B58FF11A](/claim/clm_3D46B58FF11A.md) | [clm_D1405FE577D0](/claim/clm_D1405FE577D0.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532016000078/0000875320-16-000078-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 431,608,000 United States dollar | valid 2016-06-30 to 2016-09-30 | conf 0.95 | superseded | superseded_by [clm_882D250549DB](/claim/clm_882D250549DB.md) | [clm_3D46B58FF11A](/claim/clm_3D46B58FF11A.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532016000091/0000875320-16-000091-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 413,783,000 United States dollar | valid 2016-09-30 to 2017-03-31 | conf 0.95 | superseded | superseded_by [clm_7D8A031A80DB](/claim/clm_7D8A031A80DB.md) | [clm_882D250549DB](/claim/clm_882D250549DB.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532016000107/0000875320-16-000107-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 714,718,000 United States dollar | valid 2017-03-31 to 2017-06-30 | conf 0.95 | superseded | superseded_by [clm_F514C594F662](/claim/clm_F514C594F662.md) | [clm_7D8A031A80DB](/claim/clm_7D8A031A80DB.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532017000030/0000875320-17-000030-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 544,135,000 United States dollar | valid 2017-06-30 to 2017-09-30 | conf 0.95 | superseded | superseded_by [clm_933F26C8B388](/claim/clm_933F26C8B388.md) | [clm_F514C594F662](/claim/clm_F514C594F662.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532017000047/0000875320-17-000047-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 578,165,000 United States dollar | valid 2017-09-30 to 2018-03-31 | conf 0.95 | superseded | superseded_by [clm_66E56361C26E](/claim/clm_66E56361C26E.md) | [clm_933F26C8B388](/claim/clm_933F26C8B388.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532017000060/0000875320-17-000060-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 640,799,000 United States dollar | valid 2018-03-31 to 2018-06-30 | conf 0.95 | superseded | superseded_by [clm_7A545FD3F361](/claim/clm_7A545FD3F361.md) | [clm_66E56361C26E](/claim/clm_66E56361C26E.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532018000014/0000875320-18-000014-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 752,157,000 United States dollar | valid 2018-06-30 to 2018-09-30 | conf 0.95 | superseded | superseded_by [clm_8E2ABC809D39](/claim/clm_8E2ABC809D39.md) | [clm_7A545FD3F361](/claim/clm_7A545FD3F361.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532018000022/0000875320-18-000022-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 784,535,000 United States dollar | valid 2018-09-30 to 2019-03-31 | conf 0.95 | superseded | superseded_by [clm_3E7B3994881E](/claim/clm_3E7B3994881E.md) | [clm_8E2ABC809D39](/claim/clm_8E2ABC809D39.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532018000029/0000875320-18-000029-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 858,435,000 United States dollar | valid 2019-03-31 to 2019-06-30 | conf 0.95 | superseded | superseded_by [clm_CDABAE46C981](/claim/clm_CDABAE46C981.md) | [clm_3E7B3994881E](/claim/clm_3E7B3994881E.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532019000019/0000875320-19-000019-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 941,293,000 United States dollar | valid 2019-06-30 to 2019-09-30 | conf 0.95 | superseded | superseded_by [clm_01DE6C70A804](/claim/clm_01DE6C70A804.md) | [clm_CDABAE46C981](/claim/clm_CDABAE46C981.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532019000037/0000875320-19-000037-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 949,828,000 United States dollar | valid 2019-09-30 to 2020-03-31 | conf 0.95 | superseded | superseded_by [clm_ED12A2E330B4](/claim/clm_ED12A2E330B4.md) | [clm_01DE6C70A804](/claim/clm_01DE6C70A804.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532019000057/0000875320-19-000057-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 1,515,107,000 United States dollar | valid 2020-03-31 to 2020-06-30 | conf 0.95 | superseded | superseded_by [clm_EE20986F8F62](/claim/clm_EE20986F8F62.md) | [clm_ED12A2E330B4](/claim/clm_ED12A2E330B4.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532020000019/0000875320-20-000019-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 1,524,485,000 United States dollar | valid 2020-06-30 to 2020-09-30 | conf 0.95 | superseded | superseded_by [clm_D38659C12AE8](/claim/clm_D38659C12AE8.md) | [clm_EE20986F8F62](/claim/clm_EE20986F8F62.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532020000030/0000875320-20-000030-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 1,538,271,000 United States dollar | valid 2020-09-30 to 2021-03-31 | conf 0.95 | superseded | superseded_by [clm_05E33637AD96](/claim/clm_05E33637AD96.md) | [clm_D38659C12AE8](/claim/clm_D38659C12AE8.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532020000043/0000875320-20-000043-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 1,724,305,000 United States dollar | valid 2021-03-31 to 2021-06-30 | conf 0.95 | superseded | superseded_by [clm_BA95AEDBE337](/claim/clm_BA95AEDBE337.md) | [clm_05E33637AD96](/claim/clm_05E33637AD96.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532021000015/0000875320-21-000015-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 1,793,370,000 United States dollar | valid 2021-06-30 to 2021-09-30 | conf 0.95 | superseded | superseded_by [clm_6BB57BAD5620](/claim/clm_6BB57BAD5620.md) | [clm_BA95AEDBE337](/claim/clm_BA95AEDBE337.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532021000027/0000875320-21-000027-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 1,984,164,000 United States dollar | valid 2021-09-30 to 2022-03-31 | conf 0.95 | superseded | superseded_by [clm_47EA232B8F9C](/claim/clm_47EA232B8F9C.md) | [clm_6BB57BAD5620](/claim/clm_6BB57BAD5620.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532021000033/0000875320-21-000033-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 2,097,500,000 United States dollar | valid 2022-03-31 to 2022-06-30 | conf 0.95 | superseded | superseded_by [clm_F084A45C1F3A](/claim/clm_F084A45C1F3A.md) | [clm_47EA232B8F9C](/claim/clm_47EA232B8F9C.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 2,196,200,000 United States dollar | valid 2022-06-30 to 2022-09-30 | conf 0.95 | superseded | superseded_by [clm_A07370340B6C](/claim/clm_A07370340B6C.md) | [clm_F084A45C1F3A](/claim/clm_F084A45C1F3A.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532022000030/0000875320-22-000030-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 2,334,300,000 United States dollar | valid 2022-09-30 to 2023-03-31 | conf 0.95 | superseded | superseded_by [clm_56F24DCACD81](/claim/clm_56F24DCACD81.md) | [clm_A07370340B6C](/claim/clm_A07370340B6C.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532022000038/0000875320-22-000038-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 2,374,800,000 United States dollar | valid 2023-03-31 to 2023-06-30 | conf 0.95 | superseded | superseded_by [clm_12CF2E7419A7](/claim/clm_12CF2E7419A7.md) | [clm_56F24DCACD81](/claim/clm_56F24DCACD81.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/0000875320-23-000012-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 2,493,200,000 United States dollar | valid 2023-06-30 to 2023-09-30 | conf 0.95 | superseded | superseded_by [clm_25F0B0F08F89](/claim/clm_25F0B0F08F89.md) | [clm_12CF2E7419A7](/claim/clm_12CF2E7419A7.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/0000875320-23-000021-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 2,483,500,000 United States dollar | valid 2023-09-30 to 2024-03-31 | conf 0.95 | superseded | superseded_by [clm_40945582F02C](/claim/clm_40945582F02C.md) | [clm_25F0B0F08F89](/claim/clm_25F0B0F08F89.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/0000875320-23-000031-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 2,690,600,000 United States dollar | valid 2024-03-31 to 2024-06-30 | conf 0.95 | superseded | superseded_by [clm_99B3D838F073](/claim/clm_99B3D838F073.md) | [clm_40945582F02C](/claim/clm_40945582F02C.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/0000875320-24-000139-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 2,645,600,000 United States dollar | valid 2024-06-30 to 2024-09-30 | conf 0.95 | superseded | superseded_by [clm_85558B741195](/claim/clm_85558B741195.md) | [clm_99B3D838F073](/claim/clm_99B3D838F073.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/0000875320-24-000198-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 2,771,900,000 United States dollar | valid 2024-09-30 to 2025-03-31 | conf 0.95 | superseded | superseded_by [clm_1EC0DE7E99A1](/claim/clm_1EC0DE7E99A1.md) | [clm_85558B741195](/claim/clm_85558B741195.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/0000875320-24-000223-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 2,770,200,000 United States dollar | valid 2025-03-31 to 2025-06-30 | conf 0.95 | superseded | superseded_by [clm_9B7DD75E016B](/claim/clm_9B7DD75E016B.md) | [clm_1EC0DE7E99A1](/claim/clm_1EC0DE7E99A1.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/0000875320-25-000192-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 2,964,700,000 United States dollar | valid 2025-06-30 to 2025-09-30 | conf 0.95 | superseded | superseded_by [clm_8AB184162D82](/claim/clm_8AB184162D82.md) | [clm_9B7DD75E016B](/claim/clm_9B7DD75E016B.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/0000875320-25-000216-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 3,076,400,000 United States dollar | valid 2025-09-30 to 2026-03-31 | conf 0.95 | superseded | superseded_by [clm_78B1FE0A2ECC](/claim/clm_78B1FE0A2ECC.md) | [clm_8AB184162D82](/claim/clm_8AB184162D82.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 2,986,900,000 United States dollar | valid 2026-03-31 to 2026-06-30 | conf 0.95 | superseded | superseded_by [clm_600A80B3AFE0](/claim/clm_600A80B3AFE0.md) | [clm_78B1FE0A2ECC](/claim/clm_78B1FE0A2ECC.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/0000875320-26-000173-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 3,333,900,000 United States dollar | valid 2026-06-30 to 2026-09-30 | conf 0.95 | superseded | superseded_by [clm_30E62BBC7C14](/claim/clm_30E62BBC7C14.md) | [clm_600A80B3AFE0](/claim/clm_600A80B3AFE0.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm
- [Vertex Pharmaceuticals](/record/vertex-pharmaceuticals.md) | quarterly_revenue | 3,440,800,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_30E62BBC7C14](/claim/clm_30E62BBC7C14.md)
  sources: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm

## What replaced what

- $23.98 million (2009-03-31 to 2009-06-30, [clm_8EDF57286E75](/claim/clm_8EDF57286E75.md)) was replaced by $19.06 million from 2009-06-30 ([clm_8CAD8C9EBAFE](/claim/clm_8CAD8C9EBAFE.md))
- $19.06 million (2009-06-30 to 2009-09-30, [clm_8CAD8C9EBAFE](/claim/clm_8CAD8C9EBAFE.md)) was replaced by $24.96 million from 2009-09-30 ([clm_FCBA634A768D](/claim/clm_FCBA634A768D.md))
- $24.96 million (2009-09-30 to 2010-03-31, [clm_FCBA634A768D](/claim/clm_FCBA634A768D.md)) was replaced by $22.43 million from 2010-03-31 ([clm_803A751AACB0](/claim/clm_803A751AACB0.md))
- $22.43 million (2010-03-31 to 2010-06-30, [clm_803A751AACB0](/claim/clm_803A751AACB0.md)) was replaced by $31.62 million from 2010-06-30 ([clm_91E848597DF5](/claim/clm_91E848597DF5.md))
- $31.62 million (2010-06-30 to 2010-09-30, [clm_91E848597DF5](/claim/clm_91E848597DF5.md)) was replaced by $23.8 million from 2010-09-30 ([clm_A2ABBC5D4946](/claim/clm_A2ABBC5D4946.md))
- $23.8 million (2010-09-30 to 2011-03-31, [clm_A2ABBC5D4946](/claim/clm_A2ABBC5D4946.md)) was replaced by $73.66 million from 2011-03-31 ([clm_06E54341B7F1](/claim/clm_06E54341B7F1.md))
- $73.66 million (2011-03-31 to 2011-06-30, [clm_06E54341B7F1](/claim/clm_06E54341B7F1.md)) was replaced by $114.42 million from 2011-06-30 ([clm_0CB375426AF0](/claim/clm_0CB375426AF0.md))
- $114.42 million (2011-06-30 to 2011-09-30, [clm_0CB375426AF0](/claim/clm_0CB375426AF0.md)) was replaced by $659.2 million from 2011-09-30 ([clm_AFFDEC5591E2](/claim/clm_AFFDEC5591E2.md))
- $659.2 million (2011-09-30 to 2012-03-31, [clm_AFFDEC5591E2](/claim/clm_AFFDEC5591E2.md)) was replaced by $438.74 million from 2012-03-31 ([clm_D0A8C98B8F52](/claim/clm_D0A8C98B8F52.md))
- $438.74 million (2012-03-31 to 2012-06-30, [clm_D0A8C98B8F52](/claim/clm_D0A8C98B8F52.md)) was replaced by $418.31 million from 2012-06-30 ([clm_EDB18FEAB098](/claim/clm_EDB18FEAB098.md))
- $418.31 million (2012-06-30 to 2012-09-30, [clm_EDB18FEAB098](/claim/clm_EDB18FEAB098.md)) was replaced by $336.01 million from 2012-09-30 ([clm_8B3F25617388](/claim/clm_8B3F25617388.md))
- $336.01 million (2012-09-30 to 2013-03-31, [clm_8B3F25617388](/claim/clm_8B3F25617388.md)) was replaced by $328.37 million from 2013-03-31 ([clm_7FF4DCB7FD4C](/claim/clm_7FF4DCB7FD4C.md))
- $328.37 million (2013-03-31 to 2013-06-30, [clm_7FF4DCB7FD4C](/claim/clm_7FF4DCB7FD4C.md)) was replaced by $310.75 million from 2013-06-30 ([clm_FF8C09587BDA](/claim/clm_FF8C09587BDA.md))
- $310.75 million (2013-06-30 to 2013-09-30, [clm_FF8C09587BDA](/claim/clm_FF8C09587BDA.md)) was replaced by $221.7 million from 2013-09-30 ([clm_48045D19FF6B](/claim/clm_48045D19FF6B.md))
- $221.7 million (2013-09-30 to 2014-03-31, [clm_48045D19FF6B](/claim/clm_48045D19FF6B.md)) was replaced by $118.45 million from 2014-03-31 ([clm_70C273FE1AD2](/claim/clm_70C273FE1AD2.md))
- $118.45 million (2014-03-31 to 2014-06-30, [clm_70C273FE1AD2](/claim/clm_70C273FE1AD2.md)) was replaced by $138.42 million from 2014-06-30 ([clm_52B14B1D462C](/claim/clm_52B14B1D462C.md))
- $138.42 million (2014-06-30 to 2014-09-30, [clm_52B14B1D462C](/claim/clm_52B14B1D462C.md)) was replaced by $178.99 million from 2014-09-30 ([clm_E49939D6DEDB](/claim/clm_E49939D6DEDB.md))
- $178.99 million (2014-09-30 to 2015-03-31, [clm_E49939D6DEDB](/claim/clm_E49939D6DEDB.md)) was replaced by $138.51 million from 2015-03-31 ([clm_72E202E696DB](/claim/clm_72E202E696DB.md))
- $138.51 million (2015-03-31 to 2015-06-30, [clm_72E202E696DB](/claim/clm_72E202E696DB.md)) was replaced by $166.08 million from 2015-06-30 ([clm_26173C591341](/claim/clm_26173C591341.md))
- $166.08 million (2015-06-30 to 2015-09-30, [clm_26173C591341](/claim/clm_26173C591341.md)) was replaced by $309.82 million from 2015-09-30 ([clm_86562BC405C6](/claim/clm_86562BC405C6.md))
- $309.82 million (2015-09-30 to 2016-03-31, [clm_86562BC405C6](/claim/clm_86562BC405C6.md)) was replaced by $398.08 million from 2016-03-31 ([clm_D1405FE577D0](/claim/clm_D1405FE577D0.md))
- $398.08 million (2016-03-31 to 2016-06-30, [clm_D1405FE577D0](/claim/clm_D1405FE577D0.md)) was replaced by $431.61 million from 2016-06-30 ([clm_3D46B58FF11A](/claim/clm_3D46B58FF11A.md))
- $431.61 million (2016-06-30 to 2016-09-30, [clm_3D46B58FF11A](/claim/clm_3D46B58FF11A.md)) was replaced by $413.78 million from 2016-09-30 ([clm_882D250549DB](/claim/clm_882D250549DB.md))
- $413.78 million (2016-09-30 to 2017-03-31, [clm_882D250549DB](/claim/clm_882D250549DB.md)) was replaced by $714.72 million from 2017-03-31 ([clm_7D8A031A80DB](/claim/clm_7D8A031A80DB.md))
- $714.72 million (2017-03-31 to 2017-06-30, [clm_7D8A031A80DB](/claim/clm_7D8A031A80DB.md)) was replaced by $544.14 million from 2017-06-30 ([clm_F514C594F662](/claim/clm_F514C594F662.md))
- $544.14 million (2017-06-30 to 2017-09-30, [clm_F514C594F662](/claim/clm_F514C594F662.md)) was replaced by $578.17 million from 2017-09-30 ([clm_933F26C8B388](/claim/clm_933F26C8B388.md))
- $578.17 million (2017-09-30 to 2018-03-31, [clm_933F26C8B388](/claim/clm_933F26C8B388.md)) was replaced by $640.8 million from 2018-03-31 ([clm_66E56361C26E](/claim/clm_66E56361C26E.md))
- $640.8 million (2018-03-31 to 2018-06-30, [clm_66E56361C26E](/claim/clm_66E56361C26E.md)) was replaced by $752.16 million from 2018-06-30 ([clm_7A545FD3F361](/claim/clm_7A545FD3F361.md))
- $752.16 million (2018-06-30 to 2018-09-30, [clm_7A545FD3F361](/claim/clm_7A545FD3F361.md)) was replaced by $784.54 million from 2018-09-30 ([clm_8E2ABC809D39](/claim/clm_8E2ABC809D39.md))
- $784.54 million (2018-09-30 to 2019-03-31, [clm_8E2ABC809D39](/claim/clm_8E2ABC809D39.md)) was replaced by $858.44 million from 2019-03-31 ([clm_3E7B3994881E](/claim/clm_3E7B3994881E.md))
- $858.44 million (2019-03-31 to 2019-06-30, [clm_3E7B3994881E](/claim/clm_3E7B3994881E.md)) was replaced by $941.29 million from 2019-06-30 ([clm_CDABAE46C981](/claim/clm_CDABAE46C981.md))
- $941.29 million (2019-06-30 to 2019-09-30, [clm_CDABAE46C981](/claim/clm_CDABAE46C981.md)) was replaced by $949.83 million from 2019-09-30 ([clm_01DE6C70A804](/claim/clm_01DE6C70A804.md))
- $949.83 million (2019-09-30 to 2020-03-31, [clm_01DE6C70A804](/claim/clm_01DE6C70A804.md)) was replaced by $1.52 billion from 2020-03-31 ([clm_ED12A2E330B4](/claim/clm_ED12A2E330B4.md))
- $1.52 billion (2020-03-31 to 2020-06-30, [clm_ED12A2E330B4](/claim/clm_ED12A2E330B4.md)) was replaced by $1.52 billion from 2020-06-30 ([clm_EE20986F8F62](/claim/clm_EE20986F8F62.md))
- $1.52 billion (2020-06-30 to 2020-09-30, [clm_EE20986F8F62](/claim/clm_EE20986F8F62.md)) was replaced by $1.54 billion from 2020-09-30 ([clm_D38659C12AE8](/claim/clm_D38659C12AE8.md))
- $1.54 billion (2020-09-30 to 2021-03-31, [clm_D38659C12AE8](/claim/clm_D38659C12AE8.md)) was replaced by $1.72 billion from 2021-03-31 ([clm_05E33637AD96](/claim/clm_05E33637AD96.md))
- $1.72 billion (2021-03-31 to 2021-06-30, [clm_05E33637AD96](/claim/clm_05E33637AD96.md)) was replaced by $1.79 billion from 2021-06-30 ([clm_BA95AEDBE337](/claim/clm_BA95AEDBE337.md))
- $1.79 billion (2021-06-30 to 2021-09-30, [clm_BA95AEDBE337](/claim/clm_BA95AEDBE337.md)) was replaced by $1.98 billion from 2021-09-30 ([clm_6BB57BAD5620](/claim/clm_6BB57BAD5620.md))
- $1.98 billion (2021-09-30 to 2022-03-31, [clm_6BB57BAD5620](/claim/clm_6BB57BAD5620.md)) was replaced by $2.1 billion from 2022-03-31 ([clm_47EA232B8F9C](/claim/clm_47EA232B8F9C.md))
- $2.1 billion (2022-03-31 to 2022-06-30, [clm_47EA232B8F9C](/claim/clm_47EA232B8F9C.md)) was replaced by $2.2 billion from 2022-06-30 ([clm_F084A45C1F3A](/claim/clm_F084A45C1F3A.md))
- $2.2 billion (2022-06-30 to 2022-09-30, [clm_F084A45C1F3A](/claim/clm_F084A45C1F3A.md)) was replaced by $2.33 billion from 2022-09-30 ([clm_A07370340B6C](/claim/clm_A07370340B6C.md))
- $2.33 billion (2022-09-30 to 2023-03-31, [clm_A07370340B6C](/claim/clm_A07370340B6C.md)) was replaced by $2.37 billion from 2023-03-31 ([clm_56F24DCACD81](/claim/clm_56F24DCACD81.md))
- $2.37 billion (2023-03-31 to 2023-06-30, [clm_56F24DCACD81](/claim/clm_56F24DCACD81.md)) was replaced by $2.49 billion from 2023-06-30 ([clm_12CF2E7419A7](/claim/clm_12CF2E7419A7.md))
- $2.49 billion (2023-06-30 to 2023-09-30, [clm_12CF2E7419A7](/claim/clm_12CF2E7419A7.md)) was replaced by $2.48 billion from 2023-09-30 ([clm_25F0B0F08F89](/claim/clm_25F0B0F08F89.md))
- $2.48 billion (2023-09-30 to 2024-03-31, [clm_25F0B0F08F89](/claim/clm_25F0B0F08F89.md)) was replaced by $2.69 billion from 2024-03-31 ([clm_40945582F02C](/claim/clm_40945582F02C.md))
- $2.69 billion (2024-03-31 to 2024-06-30, [clm_40945582F02C](/claim/clm_40945582F02C.md)) was replaced by $2.65 billion from 2024-06-30 ([clm_99B3D838F073](/claim/clm_99B3D838F073.md))
- $2.65 billion (2024-06-30 to 2024-09-30, [clm_99B3D838F073](/claim/clm_99B3D838F073.md)) was replaced by $2.77 billion from 2024-09-30 ([clm_85558B741195](/claim/clm_85558B741195.md))
- $2.77 billion (2024-09-30 to 2025-03-31, [clm_85558B741195](/claim/clm_85558B741195.md)) was replaced by $2.77 billion from 2025-03-31 ([clm_1EC0DE7E99A1](/claim/clm_1EC0DE7E99A1.md))
- $2.77 billion (2025-03-31 to 2025-06-30, [clm_1EC0DE7E99A1](/claim/clm_1EC0DE7E99A1.md)) was replaced by $2.96 billion from 2025-06-30 ([clm_9B7DD75E016B](/claim/clm_9B7DD75E016B.md))
- $2.96 billion (2025-06-30 to 2025-09-30, [clm_9B7DD75E016B](/claim/clm_9B7DD75E016B.md)) was replaced by $3.08 billion from 2025-09-30 ([clm_8AB184162D82](/claim/clm_8AB184162D82.md))
- $3.08 billion (2025-09-30 to 2026-03-31, [clm_8AB184162D82](/claim/clm_8AB184162D82.md)) was replaced by $2.99 billion from 2026-03-31 ([clm_78B1FE0A2ECC](/claim/clm_78B1FE0A2ECC.md))
- $2.99 billion (2026-03-31 to 2026-06-30, [clm_78B1FE0A2ECC](/claim/clm_78B1FE0A2ECC.md)) was replaced by $3.33 billion from 2026-06-30 ([clm_600A80B3AFE0](/claim/clm_600A80B3AFE0.md))
- $3.33 billion (2026-06-30 to 2026-09-30, [clm_600A80B3AFE0](/claim/clm_600A80B3AFE0.md)) was replaced by $3.44 billion from 2026-09-30 ([clm_30E62BBC7C14](/claim/clm_30E62BBC7C14.md))

## Questions this record answers

### What is Vertex Pharmaceuticals's current quarterly revenue?

$3.44 billion, dated September 30, 2026, from a primary source (sec.gov). The record asserts this claim as of November 10, 2026 (status valid, confidence 0.95).

### When did Vertex Pharmaceuticals's quarterly revenue last change?

The latest value on the record is $3.44 billion, dated September 30, 2026; before it the record holds $3.33 billion, dated June 30, 2026 and closed on September 30, 2026.

### What was Vertex Pharmaceuticals's quarterly revenue before $3.44 billion?

$3.33 billion, valid from June 30, 2026 to September 30, 2026 (status superseded), from a primary source (sec.gov).


## Read on

- This page: /record/vertex-pharmaceuticals/quarterly_revenue (markdown: /record/vertex-pharmaceuticals/quarterly_revenue.md)
- Entity twin: /record/vertex-pharmaceuticals.md · timeline: /timelines/vertex-pharmaceuticals.md
- Every company's quarterly revenue: /facts/quarterly_revenue.md

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.